J.P. Morgan Reports Strong Biopharma and Medtech Investment in First Half of 2026
Biopharma licensing value reached $166.7 billion in H1 2026, driven by milestone-heavy structures.
Biopharma M&A totaled $96 billion upfront across 80 transactions; Q2 alone accounted for $55.1 billion.
Biopharma venture funding hit $16.3 billion across 235 rounds, on pace for ~$33 billion full-year.
Biopharma IPOs raised $5 billion from 13 companies, surpassing any full-year total between 2022 and 2025.
Medtech M&A generated $48.9 billion upfront across 92 deals; Q2 accounted for $22.3 billion.
Medtech venture funding totaled $5 billion across 164 rounds, evenly split between Q1 and Q2.
Medtech licensing value reached $5.8 billion, but upfront cash was only 1%, reflecting milestone-based economics.
China-origin assets represented 42% of large-cap biopharma licensing deals with ≥$50 million upfront.
Biopharma and medtech capital markets maintained their early-year momentum through the first half of 2026, according to twin reports from J.P. Morgan. Investors continued favoring later-stage assets, established programs, and companies with clearer clinical and commercial catalysts. The data show a market that is reopening selectively rather than broadly, with substantial headline values but a strong preference for milestone-based structures that limit buyers' initial financial exposure.
Biopharma Capital Markets: Licensing, M&A, Venture Funding, and IPOs
Licensing Activity
Announced biopharma research and development licensing value reached $166.7 billion during the first half of 2026. The figures underscore the continued popularity of milestone-heavy deal structures, which allow buyers to cap upfront commitments while offering developers larger potential payments if programs meet clinical and regulatory targets.
Mergers and Acquisitions
Biopharma M&A activity generated $96 billion in upfront cash across 80 transactions during the first half of the year. Second-quarter activity alone accounted for $55.1 billion across 48 deals, marking the sector's second consecutive quarter with more than $40 billion in deal value. The report noted that acquirers remain disciplined, with the limited share paid upfront indicating that buyers continue to transfer development risk through milestones rather than assuming it at signing.
Venture Funding
Venture investors deployed $16.3 billion across 235 biopharma rounds during the first half, including $9.2 billion in the second quarter. While deal counts remained below earlier market cycles, funding was on pace to reach approximately $33 billion for the full year. The report highlights that early-stage companies continue to face a more challenging fundraising environment compared to more mature assets.
Initial Public Offerings
The biopharma IPO market showed signs of recovery. A total of 13 companies raised a combined $5 billion during the first half, which already surpasses every full-year fundraising total recorded between 2022 and 2025. This suggests renewed investor appetite for public listings in the sector, albeit concentrated among companies with clearer near-term catalysts.
Medtech Capital Markets: M&A Dominates, Venture Funding Steady, Licensing Milestone-Heavy
Mergers and Acquisitions
Medtech capital markets followed a more measured trajectory compared to biopharma, with M&A remaining the primary exit route. Acquisitions generated $48.9 billion in upfront cash across 92 deals during the first half, including $22.3 billion across 47 second-quarter transactions. The report indicates that for medtech companies, subdued IPO activity means strategic buyers are likely to remain the most practical route to liquidity.
Venture Funding
Medtech venture funding totaled $5 billion across 164 rounds, evenly divided between the first and second quarters. The funding environment remains steady but not accelerating, consistent with a market that is cautiously selective.
Licensing and R&D Partnerships
Licensing and R&D partnerships generated $5.8 billion in announced medtech value. However, upfront cash represented only 1% of that total, demonstrating the sector's heavy reliance on milestone-based economics. This mirrors the biopharma trend but is even more pronounced, reflecting the longer development timelines and higher regulatory risk typical of medtech.
Market Trends and Outlook: Selective Reopening, China-Origin Assets, Risk Transfer via Milestones
The results point to a capital market that is reopening selectively rather than broadly. Investors and acquirers are directing money toward more mature assets and programs with stronger evidence, while earlier-stage companies continue facing a more challenging fundraising environment.
China-origin assets are becoming increasingly important to biopharma dealmaking. They represented 42% of large-cap licensing transactions carrying upfront payments of at least $50 million and captured 68% of upfront dollars in those deals. This trend underscores the growing role of Chinese innovation in the global biopharma pipeline.
Across both sectors, headline deal values remain substantial, but the limited share paid upfront shows that buyers are continuing to transfer development risk through milestones rather than assuming it at signing. This disciplined approach may persist as long as macroeconomic uncertainty and regulatory pressures remain.
For medtech companies, the relative lack of IPO activity means that strategic acquisitions will likely remain the most viable exit path for venture-backed firms. In biopharma, the resumption of meaningful IPO activity suggests a broader market recovery may be underway, though it remains concentrated among later-stage companies.
Overall, the J.P. Morgan reports paint a picture of a health-care investment landscape that is cautiously optimistic, with ample capital available for de-risked assets and clear catalysts, but a more challenging environment for early-stage innovation without strong proof-of-concept data.
References
J.P. Morgan. “Biopharma and Medtech Capital Markets – H1 2026 Review.” Reports cited in source bundle.